Phosphodiesterase 4 Inhibitors
"Phosphodiesterase 4 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that specifically inhibit PHOSPHODIESTERASE 4.
| Descriptor ID |
D058988
|
| MeSH Number(s) |
D27.505.519.389.735.374
|
| Concept/Terms |
Phosphodiesterase 4 Inhibitors- Phosphodiesterase 4 Inhibitors
- Inhibitors, Phosphodiesterase 4
- PDE4 Inhibitors
- Inhibitors, PDE4
- Phosphodiesterase Type 4 Inhibitors
- PDE-4 Inhibitors
- Inhibitors, PDE-4
- PDE 4 Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase 4 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase 4 Inhibitors".
This graph shows the total number of publications written about "Phosphodiesterase 4 Inhibitors" by people in this website by year, and whether "Phosphodiesterase 4 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 5 | 3 | 8 |
| 2018 | 4 | 2 | 6 |
| 2019 | 4 | 1 | 5 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Phosphodiesterase 4 Inhibitors" by people in Profiles.
-
CuCl2-catalyzed inexpensive, faster and ligand/additive free synthesis of isoquinolin-1(2H)-one derivatives via the coupling-cyclization strategy: Evaluation of a new class of compounds as potential PDE4 inhibitors. Bioorg Chem. 2021 10; 115:105265.
-
COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast. Clin Exp Dermatol. 2021 10; 46(7):1344-1346.
-
PdCl2-catalyzed synthesis of a new class of isocoumarin derivatives containing aminosulfonyl / aminocarboxamide moiety: First identification of a isocoumarin based PDE4 inhibitor. Eur J Med Chem. 2021 Oct 05; 221:113514.
-
Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic. J Drugs Dermatol. 2021 May 01; 20(5):582-583.
-
SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights. Front Immunol. 2021; 12:635018.
-
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking. Biochem Pharmacol. 2021 03; 185:114431.
-
Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19. Pulm Pharmacol Ther. 2021 02; 66:101978.
-
Can roflumilast become steroid-sparing alternative in the treatment of COVID-19? Med Hypotheses. 2020 Nov; 144:110246.
-
Harnessing inflammation resolving-based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID-19? Br J Pharmacol. 2020 09; 177(17):3898-3904.
-
Letter to the editor: Immunomodulation by phosphodiesterase-4 inhibitor in COVID-19 patients. Metabolism. 2020 09; 110:154300.